Safety of Propranolol Therapy for Severe Infantile Hemangioma -

Safety of Propranolol Therapy for Severe Infantile Hemangioma
Information type: Other primary research
Source: Journal of the American Medical Association
Specialities: Cardiovascular system disorders | Paediatric and neonatal medicine
Summary
This prospective cohort study (n=922) of compassionate use propranolol found that serious ADRs were rare when it was used to treat severe infantile hemangiomas. However, bradycardia, bronchoreactivity and hypoglycaemia were common in children with severe comorbidities.
UKMi comment
The authors advise that prescribers must counsel parents at each follow-up visit to discontinue propranolol during fasting and intercurrent illness, especially in the setting of restricted oral intake and respiratory symptoms.
Related links: